Mean age, years (SD) |
51.9 (12.0) |
Male Gender
|
37,876 (76.7%) |
Race
Caucasian
African American
Hispanic
Asian
Other
Unknown
|
37,224 (75.4%)
7,492 (15.2%)
3,076 (6.2%)
1,078 (2.2%)
468 (1.0%)
23 (0.1%)
|
Diagnosis at Listing
Dilated Myopathy
Restrictive Myopathy
Hypertrophic Myopathy
Prior graft failure
CAD
Valvular Disease
Congenital
Other
|
35,915 (72.8%)
872 (1.8%)
811 (1.6%)
1,077 (2.2%)
7,611 (15.4%)
1,208 (2.5%)
1,030 (2.1%)
96 (0.2%)
|
Year Transplanted
October 1987 – December 2004
January 2005 – September 2018
|
26,534 (53.8%)
22,827 (46.3%)
|
Comorbidities
Mean BMI, kg/m2 (SD)
|
26.3 (4.7)
|
Mean GFR, mL/min/1.73m2 (SD)
GFR >90 (CKD stage I)
GFR 60-89 (CKD stage II)
GFR 45-59 (CKD stage IIIa)
GFR 30-44 (CKD stage IIIb)
GFR 15-29 (CKD stage IV)
GFR <15 (CKD stage V)
Unknown
|
70.0 (25.8)
9,205 (18.7%)
15,838 (32.1%)
9,011 (18.3%)
5,149 (10.4%)
1,129 (2.3%)
167 (0.3%)
8,862 (18.0%)
|
Diabetes
No
Yes
Unknown
|
29,925 (60.6%)
8,993 (18.2%)
10,443 (21.2%)
|
History of smoking
No
Yes
Unknown
|
12,226 (24.8%)
10,960 (22.2%)
26,175 (53.0%)
|
Cerebrovascular disease
No
Yes
Unknown
|
36,909 (74.8%)
1,776 (3.6%)
10,676 (21.6%)
|
History of Cancer
No
Yes
Unknown
|
38,331 (77.7%)
269 (0.5%)
10,761 (21.8%)
|
Infectious Disease Serology
HBV Core Antibody
Negative
Positive
Unknown
|
35,430 (71.8%)
1,622 (3.3%)
12,309 (24.9%)
|
HCV Serostatus
Negative
Positive
Unknown
|
39,651 (80.3%)
838 (1.7%)
8,872 (18.0%)
|
CMV Status
Negative
Positive
Unknown
|
11,660 (23.6%)
19,493 (39.5%)
18,208 (36.9%)
|
EBV Serostatus
Negative
Positive
Unknown
|
3,375 (6.8%)
22,125 (44.8%)
23,861 (48.4%)
|
Post-Op Complications
Stroke
Yes
No
Unknown
|
676 (1.4%)
38,513 (78.0%)
10,172 (20.6%)
|
Dialysis
Yes
No
Unknown
|
2,249 (4.6%)
36,964 (74.9%)
10,148 (20.6%)
|
Induction Therapy
Basiliximab
ATG
|
36,384 (73.7%)
6,113 (12.4%)
7,511 (15.2%)
|
Maintenance Therapy
Calcineurin inhibitor
mTOR inhibitor
MMF
Steroid
|
43,689 (88.5%)
896 (1.8%)
30,405 (61.6%)
43,171 (87.5%)
|